Ghent University Academic Bibliography

Advanced

Dichotomous function of IL-33 in health and disease: From biology to clinical implications

Harald Braun UGent, Inna Afonina UGent, Christina Mueller and Rudi Beyaert UGent (2018) BIOCHEMICAL PHARMACOLOGY. 148. p.238-252
abstract
Interleukin (IL)-33 is a cytokine that is released from epithelial and endothelial cells at barrier surfaces upon tissue stress or damage to operate as an alarmin. IL-33 has been primarily implicated in the induction of T helper (Th) 2 type immune responses. Therefore, IL-33 has attracted a lot of interest as a potential therapeutic target in asthma and other allergic diseases. Over the years, it has become clear that IL-33 has a much broader activity and also contributes to Th1 immunity, expanding the possibilities for therapeutic modulation of IL-33 activity to multiple inflammatory diseases. However, more recently IL-33 has also been shown to mediate immunosuppression and tissue repair by activating regulatory T cells (Treg) and promoting M2 macrophage polarization. These pleiotropic activities of IL-33 illustrate the need for a tight molecular regulation of IL-33 activity, and have to be taken into account when IL-33 or its receptor is targeted for therapeutic modulation. Here we review the multiple molecular mechanisms that regulate IL-33 activity and describe how I -33 can shape innate and adaptive immune responses by promoting Th1, Th2 and Treg function. Finally, we will discuss the possibilities for therapeutic modulation of IL-33 signaling as well as possible safety issues. (C) 2018 Elsevier Inc. All rights reserved.
Please use this url to cite or link to this publication:
author
organization
year
type
journalArticle (original)
publication status
published
subject
keyword
INNATE LYMPHOID-CELLS, REGULATORY T-CELLS, RECEPTOR ACCESSORY PROTEIN, EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS, ALTERNATIVELY ACTIVATED, MACROPHAGES, AMELIORATES EXPERIMENTAL COLITIS, CONTROLS ALLERGIC, SENSITIZATION, HUMAN EPIDERMAL-KERATINOCYTES, THYMIC STROMAL, LYMPHOPOIETIN, INDUCED AIRWAY INFLAMMATION, IL-33, Allergy, Asthma, Inflammation, Signaling, Immunity
journal title
BIOCHEMICAL PHARMACOLOGY
Biochem. Pharmacol.
volume
148
pages
15 pages
publisher
Pergamon-elsevier Science Ltd
place of publication
Oxford
Web of Science type
Article
Web of Science id
000426141200021
ISSN
0006-2952
1873-2968
DOI
10.1016/j.bcp.2018.01.010
language
English
UGent publication?
yes
classification
U
id
8555794
handle
http://hdl.handle.net/1854/LU-8555794
date created
2018-03-15 09:40:59
date last changed
2018-03-15 09:40:59
@article{8555794,
  abstract     = {Interleukin (IL)-33 is a cytokine that is released from epithelial and endothelial cells at barrier surfaces upon tissue stress or damage to operate as an alarmin. IL-33 has been primarily implicated in the induction of T helper (Th) 2 type immune responses. Therefore, IL-33 has attracted a lot of interest as a potential therapeutic target in asthma and other allergic diseases. Over the years, it has become clear that IL-33 has a much broader activity and also contributes to Th1 immunity, expanding the possibilities for therapeutic modulation of IL-33 activity to multiple inflammatory diseases. However, more recently IL-33 has also been shown to mediate immunosuppression and tissue repair by activating regulatory T cells (Treg) and promoting M2 macrophage polarization. These pleiotropic activities of IL-33 illustrate the need for a tight molecular regulation of IL-33 activity, and have to be taken into account when IL-33 or its receptor is targeted for therapeutic modulation. Here we review the multiple molecular mechanisms that regulate IL-33 activity and describe how I -33 can shape innate and adaptive immune responses by promoting Th1, Th2 and Treg function. Finally, we will discuss the possibilities for therapeutic modulation of IL-33 signaling as well as possible safety issues. (C) 2018 Elsevier Inc. All rights reserved.},
  author       = {Braun, Harald and Afonina, Inna and Mueller, Christina and Beyaert, Rudi},
  issn         = {0006-2952},
  journal      = {BIOCHEMICAL PHARMACOLOGY},
  keyword      = {INNATE LYMPHOID-CELLS,REGULATORY T-CELLS,RECEPTOR ACCESSORY PROTEIN,EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS,ALTERNATIVELY ACTIVATED,MACROPHAGES,AMELIORATES EXPERIMENTAL COLITIS,CONTROLS ALLERGIC,SENSITIZATION,HUMAN EPIDERMAL-KERATINOCYTES,THYMIC STROMAL,LYMPHOPOIETIN,INDUCED AIRWAY INFLAMMATION,IL-33,Allergy,Asthma,Inflammation,Signaling,Immunity},
  language     = {eng},
  pages        = {238--252},
  publisher    = {Pergamon-elsevier Science Ltd},
  title        = {Dichotomous function of IL-33 in health and disease: From biology to clinical implications},
  url          = {http://dx.doi.org/10.1016/j.bcp.2018.01.010},
  volume       = {148},
  year         = {2018},
}

Chicago
Braun, Harald, Inna Afonina, Christina Mueller, and Rudi Beyaert. 2018. “Dichotomous Function of IL-33 in Health and Disease: From Biology to Clinical Implications.” Biochemical Pharmacology 148: 238–252.
APA
Braun, H., Afonina, I., Mueller, C., & Beyaert, R. (2018). Dichotomous function of IL-33 in health and disease: From biology to clinical implications. BIOCHEMICAL PHARMACOLOGY, 148, 238–252.
Vancouver
1.
Braun H, Afonina I, Mueller C, Beyaert R. Dichotomous function of IL-33 in health and disease: From biology to clinical implications. BIOCHEMICAL PHARMACOLOGY. Oxford: Pergamon-elsevier Science Ltd; 2018;148:238–52.
MLA
Braun, Harald, Inna Afonina, Christina Mueller, et al. “Dichotomous Function of IL-33 in Health and Disease: From Biology to Clinical Implications.” BIOCHEMICAL PHARMACOLOGY 148 (2018): 238–252. Print.